Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.
Management will host one-on-one investor meetings and provide live audio webcasts and replays via the company investor events website.
Positive
- None.
Negative
- None.
News Market Reaction – SYRE
In the Feb 25 session, SYRE gained 0.99%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings and update | Positive | +1.6% | Reported 2025 results, strong cash runway and multiple 2026 proof-of-concept readouts. |
| Feb 18 | Scientific presentations | Positive | +1.8% | ECCO data on SPY003, SKYLINE trial and superior dual-targeting preclinical results. |
| Feb 06 | Inducement awards | Neutral | -3.3% | Granted 30,200 inducement stock options to new employees under equity plan. |
| Jan 23 | Inducement award CCO | Neutral | +0.8% | Equity inducement grant for newly appointed Chief Commercial Officer under 2018 plan. |
| Jan 12 | 2026 outlook | Positive | +7.2% | Outlined six 2026 POC readouts and cash balance expected to fund into H2 2028. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news tied to pipeline progress, strategy, and financial strength has generally been met with positive price reactions, while administrative equity grants saw the only notable pullback.
Over the last months, Spyre highlighted a transformational 2026 with six planned proof-of-concept readouts and reported strong cash resources, including $756.5M at year-end 2025 and an October 2025 raise. Scientific visibility increased via ECCO presentations on SPY003 and the SKYLINE platform. Administrative items such as inducement option grants produced mixed, mostly modest reactions. Against this backdrop, today’s March investor-conference participation fits a pattern of active investor and scientific engagement layered on top of a well-funded, data-rich 2026 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: TD Cowen 46th Annual Health Care Conference - Boston
Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET
Event: Leerink Global Healthcare Conference – Miami
Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET
Event: Jefferies Biotech on the Beach Summit – Miami
Date: Tuesday, March 10, 2026
Members of the Spyre management team will host one-on-one investor meetings during the conferences.
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com
